

Why should you attend?

This practical one day course will provide an overview of Intellectual Property (IP) for those working in regulatory affairs. IP is a fundamental contributing factor to the overall regulatory strategic approach that a company may take and recognition of the different aspects of IP and influences is essential in modern regulatory affairs. Attendance will enable you to understand IP aspects and their impact and influence on regulatory strategy. Key issues covered will include patents, trademarks and copyright as well as data and market exclusivity for global pharmaceutical products. The course will also discuss the EU and FDA regulatory process, highlighting one of the fundamental differences between EU and US systems and the link to patents.

Who should attend

This seminar will be of interest to development and regulatory managers working in the pharmaceutical industry. It will also be relevant to anyone requiring an overview of the key IP issues relating to regulatory affairs.

Expert trainer



Andrew Willis, currently works as an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously,

Andrew worked for Catalent Pharma Solutions as VP Regulatory Affairs and Consulting Services. Catalent is the world's leading contract manufacturer and distributor of pharmaceuticals, and Andrew was head of a team of internal and external regulatory affairs consultants.

Andrew qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He has ten years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs.

Andrew currently has a total of twenty eight years pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.

A certificate of attendance for professional development will be available to each participant who completes the course



Management Forum in-house training

If you have five or more participants who could benefit from this training then we can come to you. Our expert comes to you, saving you time and money. To get a **FREE** consultation and to find out how we can work with you call **Aleksandra**, our in-house training expert, on **+44 (0) 20 7749 4730** or email **inhouse@management-forum.co.uk**

To find out more please visit: **management-forum.co.uk**

Programme

- ▶ **Introduction and welcome**
- ▶ **What is Intellectual Property (IP)**
 - An overview of:
 - Patents
 - Exclusivity
 - Copyright
 - Trade secrets
- ▶ **What is a patent**
 - Defining the patent
 - Uses of a patent
 - Patents and generic developments
 - Generic legislation for the EU
 - Understanding freedom to operate
- ▶ **Global exclusivity**
 - Data exclusivity in the US
 - Data and market exclusivity in the EU
 - Global overview of exclusivity
- ▶ **Influence of IP on regulatory strategy**
 - US paragraph
 - Patent declaration
 - Overlap of patents and exclusivity
- ▶ **Product naming and trademarks**
- ▶ **Copyright**
 - The influence and impact on regulatory affairs
- ▶ **Practical exercise on FDA regulatory process and link to patents**
- ▶ **Special cases**
 - Paediatric legislation
 - Orphan drugs
- ▶ **Use of patents in development strategy**
- ▶ **Close of meeting**

